We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
About this guideline
Overseas effective date: 2 July 2012
Replaces: CPMP/EWP/563/95 Rev 1. Guideline on clinical investigation of medicinal products in the treatment of Parkinson's disease (Adopted by TGA 25 February 2009)
Note: To be read in conjunction with the Questions and answers on additional clarification for inclusion criteria in the “Guideline on clinical investigation of medicinal products in the treatment of Parkinson's disease” rev. 2 (EMA/351466/2012).
Categories: Clinical efficacy and safety | Nervous system
TGA annotations: Nil
- Where EU guidelines adopted in Australia include references to EU legislation (including EC Directives and Regulations), the requirements contained in the referenced EU legislation are not applicable to the evaluation of medicines by the TGA.
- All documents and other content published by the European Medicines Agency (EMA) on this website are under the copyright and other intellectual property rights ownership of the EMA. Please refer to Legal notice | European Medicines Agency for further information.
For more information see International scientific guidelines adopted in Australia.